[{"address1": "Paasheuvelweg 25", "city": "Amsterdam", "zip": "1105 BP", "country": "Netherlands", "phone": "31 20 240 6000", "website": "https://www.uniqure.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in Phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.", "fullTimeEmployees": 209, "companyOfficers": [{"maxAge": 1, "name": "Mr. Matthew Craig Kapusta CPA", "age": 52, "title": "CEO & Executive Director", "yearBorn": 1972, "fiscalYear": 2024, "totalPay": 1127977, "exercisedValue": 32490, "unexercisedValue": 2761994}, {"maxAge": 1, "name": "Mr. Christian  Klemt", "age": 51, "title": "CFO, Principal Financial Officer & GM of Amsterdam Site", "yearBorn": 1973, "fiscalYear": 2024, "totalPay": 679793, "exercisedValue": 0, "unexercisedValue": 282015}, {"maxAge": 1, "name": "Dr. Jeannette  Potts J.D., Ph.D.", "age": 62, "title": "Chief Legal & Compliance Officer and Corporate Secretary", "yearBorn": 1962, "fiscalYear": 2024, "totalPay": 738547, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Walid  Abi-Saab M.D.", "age": 59, "title": "Chief Medical Officer", "yearBorn": 1965, "fiscalYear": 2024, "totalPay": 946132, "exercisedValue": 0, "unexercisedValue": 268795}, {"maxAge": 1, "name": "Prof. Hugo  Katus", "title": "Chairman of Scientific Advisory Board and Managing Director of UniQure-Germany", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Amin  Abujoub Ph.D.", "title": "Chief Technical Operations Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Richard  Porter Ph.D.", "age": 56, "title": "Chief Business & Scientific Officer", "yearBorn": 1968, "fiscalYear": 2024, "totalPay": 732169, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Chiara Elizabeth Russo", "title": "Senior Director of Investor Relations", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Tamara  Tugal Ph.D., MBA", "title": "Business Development Director", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Erin  Boyer", "title": "Chief People & Culture Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 8, "boardRisk": 4, "compensationRisk": 4, "shareHolderRightsRisk": 1, "overallRisk": 3, "governanceEpochDate": 1759276800, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 59.33, "open": 60.86, "dayLow": 60.0172, "dayHigh": 62.27, "regularMarketPreviousClose": 59.33, "regularMarketOpen": 60.86, "regularMarketDayLow": 60.0172, "regularMarketDayHigh": 62.27, "payoutRatio": 0.0, "beta": 0.563, "forwardPE": -19.937908, "volume": 1008352, "regularMarketVolume": 1008352, "averageVolume": 3265587, "averageVolume10days": 1833090, "averageDailyVolume10Day": 1833090, "bid": 44.59, "ask": 76.97, "bidSize": 2, "askSize": 2, "marketCap": 3758446080, "fiftyTwoWeekLow": 5.35, "fiftyTwoWeekHigh": 65.14, "allTimeHigh": 82.49, "allTimeLow": 3.73, "priceToSalesTrailing12Months": 262.15012, "fiftyDayAverage": 35.4145, "twoHundredDayAverage": 19.17515, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 3492413440, "profitMargins": 0.0, "floatShares": 37042859, "sharesOutstanding": 61603771, "sharesShort": 7573225, "sharesShortPriorMonth": 8274589, "sharesShortPreviousMonthDate": 1757894400, "dateShortInterest": 1760486400, "sharesPercentSharesOut": 0.1229, "heldPercentInsiders": 0.0541, "heldPercentInstitutions": 0.87717, "shortRatio": 1.09, "shortPercentOfFloat": 0.1244, "impliedSharesOutstanding": 61603771, "bookValue": -0.073, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1751241600, "netIncomeToCommon": -198995008, "trailingEps": -3.9, "forwardEps": -3.06, "enterpriseToRevenue": 243.594, "enterpriseToEbitda": -23.849, "52WeekChange": 8.133233, "SandP52WeekChange": 0.16625166, "quoteType": "EQUITY", "currentPrice": 61.01, "targetHighPrice": 108.9508, "targetLowPrice": 55.849712, "targetMeanPrice": 74.85914, "targetMedianPrice": 71.31325, "recommendationMean": 1.33333, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 10, "totalCash": 376974016, "totalCashPerShare": 6.871, "ebitda": -146439008, "totalDebt": 521956000, "quickRatio": 9.347, "currentRatio": 9.982, "totalRevenue": 14337000, "revenuePerShare": 0.277, "returnOnAssets": -0.15385, "returnOnEquity": -4.2746797, "grossProfits": -121873000, "freeCashflow": -111588128, "operatingCashflow": -173436992, "revenueGrowth": -0.527, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": -7.90783, "financialCurrency": "USD", "symbol": "QURE", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "regularMarketChangePercent": 2.83161, "regularMarketPrice": 61.01, "marketState": "CLOSED", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1391610600000, "postMarketChangePercent": 1.29487, "postMarketPrice": 61.8, "postMarketChange": 0.790001, "regularMarketChange": 1.68, "regularMarketDayRange": "60.0172 - 62.27", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 3265587, "fiftyTwoWeekLowChange": 55.66, "fiftyTwoWeekLowChangePercent": 10.403738, "fiftyTwoWeekRange": "5.35 - 65.14", "fiftyTwoWeekHighChange": -4.130001, "fiftyTwoWeekHighChangePercent": -0.06340192, "fiftyTwoWeekChangePercent": 813.3233, "earningsTimestamp": 1753792200, "earningsTimestampStart": 1762259400, "earningsTimestampEnd": 1762259400, "earningsCallTimestampStart": 1753792200, "earningsCallTimestampEnd": 1753792200, "isEarningsDateEstimate": true, "corporateActions": [], "postMarketTime": 1761350066, "regularMarketTime": 1761336001, "exchange": "NMS", "messageBoardId": "finmb_171029664", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "shortName": "uniQure N.V.", "longName": "uniQure N.V.", "epsTrailingTwelveMonths": -3.9, "epsForward": -3.06, "epsCurrentYear": -2.7281, "priceEpsCurrentYear": -22.363548, "fiftyDayAverageChange": 25.595497, "fiftyDayAverageChangePercent": 0.7227406, "twoHundredDayAverageChange": 41.834846, "twoHundredDayAverageChangePercent": 2.181722, "priceToBook": -835.7534, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "1.3 - Strong Buy", "cryptoTradeable": false, "displayName": "uniQure", "trailingPegRatio": null, "__fetch_time": "2025-10-25"}]